中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
CHINESE JOURNAL OF BIOCHEMICAL PHARMACEUTICS
2014年
1期
111-112,115
,共3页
希罗达%晚期结直肠癌%临床疗效
希囉達%晚期結直腸癌%臨床療效
희라체%만기결직장암%림상료효
Xeloda (Capecitabine)%advanced colorectal cancer%clinical effects
目的：观察希罗达单药治疗晚期结直肠癌的临床疗效，探讨影响近期疗效的相关因素。方法78例晚期结直肠癌患者予以口服希罗达每日2500 mg/m 2，分早晚各1次，餐后服用，连续服用14天后停药7天。治疗周期为21天，至少治疗2个周期。观察患者近期疗效，采用Logistic回归分析影响疗效的因素。结果本组完全缓解（complete response,CR）5例，部分缓解（partial response,PR）20例，病情稳定（stable disease,SD）31例，病情进展（progress disease,PD）22例，总有效率32.05%。Logistic回归分析显示希罗达治疗无效的独立危险因素有年龄（OR=1.52,95%CI 1.015～2.319）、空腹血糖（OR=1.30,95%CI 1.483～3.677）、白蛋白（OR=1.98,95%CI 1.526～2.572）、丙氨酸氨基转移酶（OR=2.37,95%CI 1.621～3.509）、门冬氨酸氨基转移酶（OR=2.21,95%CI 1.526～2.572）。结论希罗达单药治疗晚期结直肠癌疗效确切，但治疗无效率也较高，与多种因素有关，应对患者病情进行综合评估，采用有效的治疗方法，以提高近期临床疗效。
目的：觀察希囉達單藥治療晚期結直腸癌的臨床療效，探討影響近期療效的相關因素。方法78例晚期結直腸癌患者予以口服希囉達每日2500 mg/m 2，分早晚各1次，餐後服用，連續服用14天後停藥7天。治療週期為21天，至少治療2箇週期。觀察患者近期療效，採用Logistic迴歸分析影響療效的因素。結果本組完全緩解（complete response,CR）5例，部分緩解（partial response,PR）20例，病情穩定（stable disease,SD）31例，病情進展（progress disease,PD）22例，總有效率32.05%。Logistic迴歸分析顯示希囉達治療無效的獨立危險因素有年齡（OR=1.52,95%CI 1.015～2.319）、空腹血糖（OR=1.30,95%CI 1.483～3.677）、白蛋白（OR=1.98,95%CI 1.526～2.572）、丙氨痠氨基轉移酶（OR=2.37,95%CI 1.621～3.509）、門鼕氨痠氨基轉移酶（OR=2.21,95%CI 1.526～2.572）。結論希囉達單藥治療晚期結直腸癌療效確切，但治療無效率也較高，與多種因素有關，應對患者病情進行綜閤評估，採用有效的治療方法，以提高近期臨床療效。
목적：관찰희라체단약치료만기결직장암적림상료효，탐토영향근기료효적상관인소。방법78례만기결직장암환자여이구복희라체매일2500 mg/m 2，분조만각1차，찬후복용，련속복용14천후정약7천。치료주기위21천，지소치료2개주기。관찰환자근기료효，채용Logistic회귀분석영향료효적인소。결과본조완전완해（complete response,CR）5례，부분완해（partial response,PR）20례，병정은정（stable disease,SD）31례，병정진전（progress disease,PD）22례，총유효솔32.05%。Logistic회귀분석현시희라체치료무효적독립위험인소유년령（OR=1.52,95%CI 1.015～2.319）、공복혈당（OR=1.30,95%CI 1.483～3.677）、백단백（OR=1.98,95%CI 1.526～2.572）、병안산안기전이매（OR=2.37,95%CI 1.621～3.509）、문동안산안기전이매（OR=2.21,95%CI 1.526～2.572）。결론희라체단약치료만기결직장암료효학절，단치료무효솔야교고，여다충인소유관，응대환자병정진행종합평고，채용유효적치료방법，이제고근기림상료효。
Objective To explore the clinical effects of single-agent Xeloda (Capecitabine) therapy and the related risk factors in patients with advanced colorectal cancer. Method Seventy-eight patients with advanced colorectal cancer were treated with oral Xeloda, 1250 mg/m 2 twice daily, on days 1-14 every 21 days. At least 2 cycles were administered. The short-term clinical effects were evaluated, and the related risk factors were tested by Logistic regression analysis. Results The overall response rate was 32.05%with 5 cases complete response (CR), 20 cases partial response (PR), 31 cases stable disease (SD), 22 cases progress disease (PD). The Logistic regression analysis showed that the age (OR=1.52, 95%CI 1.015~2.319), fast blood glucose (OR=1.30, 95%CI 1.483~3.677), albumin (OR=1.98, 95%CI 1.526~2.572), ALT (OR=2.37, 95%CI 1.621~3.509) and AST (OR=2.21, 95%CI 1.526~2.572) were independent risk factors for inefficient treatment. Conclusion The single-agent Xeloda (Capecitabine) is an efficacious treatment for the patients with advanced colorectal cancer. However, the inefficient rate is also high and it relates to a variety of factors. We should comprehensively evaluate the patients to improve the short-term clinical effects.
